bile duct adenocarcinoma (Cancer)
Information
- Disease name
- bile duct adenocarcinoma
- Disease ID
- DOID:4896
- Description
- "A bile duct carcinoma that derives_from epithelial cells of glandular origin." [url:http\://en.wikipedia.org/wiki/Adenocarcinoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04042831 | Recruiting | Phase 2 | Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations | June 24, 2020 | March 30, 2025 |
| NCT06092645 | Recruiting | Phase 2 | Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma | October 30, 2023 | October 31, 2025 |
| NCT03117855 | Withdrawn | Phase 1 | Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery | December 2016 |
- Disase is a (Disease Ontology)
- DOID:4897
- Cross Reference ID (Disease Ontology)
- NCI:C27813
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:70179006
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1370800